



National Association of State Controlled Substances Authorities

NASCSA Resolution 2023-02 October 2023 Minneapolis, Minnesota

A Resolution Supporting the Enhanced Control of Xylazine

WHEREAS, the illicit use of xylazine presents an urgent threat to public health and safety; and

WHEREAS, xylazine is only approved by the Food and Drug Administration (FDA) for veterinary use and not for human use; and

WHEREAS, the proliferation of xylazine as an additive to illicit drugs such as fentanyl, heroin, cocaine and other narcotics threatens to exacerbate the opioid public health emergency; and

WHEREAS, the physical effects of xylazine use in humans can include depressed breathing and heart rate, unconsciousness, and necrosis sometimes leading to amputation or other permanent physical health consequences; and

WHEREAS, xylazine exposure has resulted in intentional and unintentional fatal overdosing and there is no currently FDA-approved drug to reverse the effect of xylazine in humans; and

WHEREAS, the Drug Enforcement Administration (DEA) has issued a Public Safety Alert, warning that xylazine and fentanyl drug mixtures place users at a higher risk of fatal drug poisoning; and

WHEREAS, the White House Office of National Drug Control Policy (ONDCP) has officially designated fentanyl adulterated or associated with xylazine as an emerging threat to the United States; and

WHEREAS, several states are regulating xylazine as a controlled substance to help limit further proliferation of its illicit use; and


WHEREAS, public health departments and poison control centers across the nation have also issued advisories and alerts regarding xylazine; and

WHEREAS, prompt action to more stringently regulate illicitly-used xylazine will help limit its further proliferation, saving lives; and

WHEREAS, the illicit use of xylazine continues to grow nationally, with efforts underway in the federal agencies and Congress to address the growing crisis;

THEREFORE, BE IT RESOLVED, that the National Association State Controlled Substance Authorities (NASCSA) supports passage of those bills currently before Congress; and

BE IT FURTHER RESOLVED, that NASCSA supports legislation and/or regulations in states, commonwealths, districts or territories to further regulate xylazine to include required registration, reporting, recordkeeping and security as well as increased penalties for unlawful manufacturing or distribution and other means necessary to limit the illicit use of the drug while ensuring availability for legitimate veterinary use.

ATTEST: 

Alan McGill, President

Date: October 25, 2023